Abstract
Cancer is the second leading cause of noncommunicable disease deaths in the world. In 2018, there were over 18 million new cancer cases and approximately 10 million people died from the disease globally. In 2019, almost two million new cases of cancer will be diagnosed in USA and over 600,000 people are expected to die from the disease. The incidence of cancer is expected to rise because of lifestyle changes and a rapidly aging population. Evidence suggests that early detection is critical to reducing cancer morbidity and mortality. In this paper, the development of an integrated smart wearable and biomarker detection system is proposed to help reduce cancer morbidity and mortality. The potential benefits and limitations of the system are discussed.
Highlights
The future of effective cancer treatment and management profoundly hinges upon the use of innovative methods, which will assist clinicians in disease management. An integrated system such as integrated smart wearable and biomarker detection system (ISWEBDS) will maximize the utility of biomarkers and the addition of biosensors and wearables will help in capturing labile biomarkers in the cancer microenvironment
ISWEBDS could quickly determine the best treatment options, which is most likely to be successful reducing the problem of drug resistance
ISWEBDS can transform the problem of cancer by aiding in early detection, prevention, prognosis, recurrence and the prediction of treatment efficacy and doing so at a future science group
Summary
The need for a better approach to reduce the incidence and morbidity from cancer cannot be overemphasized. An integrated smart wearable and biomarker detection system (ISWEBDS), consisting of electrochemical biosensors to detect clinically relevant biomarkers and transmit the data to a smart wearable, will provide a novel and powerful tool that can revolutionize healthcare It could help the treatment of chronic diseases, like cancer, by enhancing early detection, diagnosis, prognosis and the understanding of pharmacological responses or outcomes to therapeutic intervention. These electrochemical biosensors will be implanted in parts of the body most prone to carcinogenesis (colon, breast, esophagus, lung, stomach, cervix and prostate or anywhere in the body considered clinically useful) and be used to monitor the microenvironment for targeted cancer biomarkers in real time.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
